Much is known regarding the antibiotic susceptibility of planktonic cultures of Mycobacterium 27 tuberculosis, the bacterium responsible for the lung disease tuberculosis (TB). As planktonically-28 grown M. tuberculosis are unlikely to be entirely representative of the bacterium during infection, 29
Introduction 40
The bacterium Mycobacterium tuberculosis is responsible for the lung disease tuberculosis (TB). It is 41 estimated that one third of the world's population is infected with this deadly pathogen. 1 While TB 42 represents a huge burden on health care systems in its own right, it also complicates other serious 43 illnesses such as HIV/AIDS. 1 New compounds are desperately required to shorten the current TB 44 treatment regimes, which routinely last longer than 6 months, and to combat the rise of resistant M. 45 tuberculosis strains. Drug-resistant TB leads to extended hospital stays and treatment times and, in 46 the worst case scenario, untreatable disease. 2, 3 47 Bacterial cells present in an infected host can display a range of phenotypes and occupy several 48 divergent physiological niches. 4, 5 For example, during infection, cells of M. tuberculosis can be both 49 replicative and non-replicative 6 and occupy a number of different niches, including macrophages 7 50 and necrotic and non-necrotic lesions. 8 M. tuberculosis growing in such diverse environments is 51 unlikely to be accurately reflected by planktonically-grown laboratory cultures. Many bacteria can 52 form microcolonies called biofilms, which can contain a mixture of replicating and non-replicating 53 cells, and cells in different metabolic states. 9, 10 Bacteria can form biofilms at the interface between a 54 surface and the surrounding air or liquid. Alternatively, floating biofilms can form at a liquid/air 55 interface. These floating biofilms are also known as pellicles. Within a biofilm or pellicle, bacterial 56 cells are more resistant to disinfection and drug treatment and therefore represent a much harder target to sterilise. 11, 12 As such, the biofilm/pellicle represents a useful model for investigating the 58 efficacy of antibacterial treatments. 59 M. tuberculosis can form pellicles in vitro 13 and the presence of microcolonies of extracellular M. 60 tuberculosis in animal models has led to speculation that these are biofilms formed in vivo. 14 Some 61 sources point to the possible presence of pellicles in the lung-air interface present in secondary TB in 62 humans; [15] [16] [17] and indicate that the susceptibility of this phenotype to antibacterial compounds is of 63 particular relevance from a treatment standpoint. Here we describe the use of bioluminescently-64 tagged M. tuberculosis to investigate the susceptibility of pellicle cells to a range of anti-65 mycobacterial compounds, including those in current clinical use as well as a selection of 66 experimental compounds. 67
Materials and methods 68

Strains and growth conditions 69
In this study we used M. tuberculosis BSG001 18 , a stable bioluminescent derivative of H37Rv 70 transformed with the integrating plasmid pMV306hspLuxABG13CDE. 19 Cultures of BSG001 were 71 grown at 37°C with gentle shaking (100rpm) in Middlebrook 7H9 broth (Fort Richard, Auckland) 72 supplemented with 10% Middlebrook ADC enrichment media (Fort Richard) and 0.5% glycerol 73 (Sigma-Aldrich), or on 7H11 agar (Fort Richard) supplemented with 10% Middlebrook OADC 74 enrichment media (Fort Richard) and 0.5% glycerol. We grew pellicles in sterile, black 96 well plates 75 (Nunc) using a previously described method. 11 Briefly, we grew M. tuberculosis BSG001 in liquid 76 culture for 2 weeks at 37°C and then adjusted the cultures to give an optical density at 600nm 77 (OD 600 ) of 1.0, before diluting them 1:100 in modified Sauton's media (0.5 g/L KH 2 PO 4 , 0.5 g/L 78 MgSO 4 , 4 g/L L-Asparagine, 2 g/L Citric acid, 0.05 g/L Ferric Ammonium Citrate, 60 mL/L glycerol, 79 0.1% ZnSO 4 , pH 7.0 [all chemicals from Sigma-Aldrich]) and adding 100 µL aliquots to each inner well 80 of a 96 well plate. We filled the outer wells with 200 µL of sterile water to reduce evaporation from 81 the M. tuberculosis containing wells. We incubated the cultures without shaking for 8 weeks at 37°C. 82 83
Determination of compound activity 84
Once pellicles had established, we determined how much media remained in the wells by removing 85 all liquid from 12 non-tested wells and taking an average volume. This is necessary as some 86 evaporation occurs because of the long incubation time, and this has to be accounted for when 87 calculating final compound concentrations. Similar levels of liquid were lost from all wells tested. We added test compounds (Table 1 & Concentrations of each compound were chosen based on the minimum inhibitory concentrations 92 (MIC) for planktonically-grown M. tuberculosis BSG001, which vary greatly between the compounds 93 tested. We tested up to 1000-fold the planktonic MIC concentration, depending on the solubility of 94 the test compound. Each concentration was done in duplicate, using three independent BSG001 95 cultures. Biofilms were incubated for a further 7 days at 37°C with no shaking and light levels (given 96
as Relative Light Units [RLU]) were measured before and after treatment using a Victor X-3 97 luminometer (Perkin Elmer). We have defined the MIC as causing a 1 log reduction in light 98 production, as previously described. 20 99
To determine the minimum bactericidal concentration (MBC), pellicles were removed from the 100 wells, disrupted by pipetting and washed 3 times in Sauton's media supplemented with 0.05% tween 101 80. The cells were then resuspended in fresh 7H9 broth (5ml, supplemented as described above) 102 and plated onto 7H11 agar (supplemented as described above). We have defined the MBC as the 103 concentration which resulted in no growth. We incubated broth cultures for 2 weeks and plate 104 cultures for 8 weeks to recover any surviving bacteria. All experiments were performed using three 105 biological replicates of M. tuberculosis BSG001 and two technical replicates. Biological replicates 106
were grown separately and tested on different days. 107
Results 108
Decreased susceptibility of pellicle-grown M. tuberculosis to front-line and experimental 109
compounds. 110
Of the four main first line drugs only rifampicin was seen to inhibit pellicles of M. tuberculosis at the 111 concentrations tested (Table 1, Fig. 2B, Fig. 3B ). Isoniazid also led to some inhibition but below the 112 threshold defined (Fig. 2C, Fig. 3C ). In the case of rifampicin the MIC and MBC for pellicle-grown 113 BSG001 were determined to be 4 mg/L, 100 times the concentration required to produce a similar 114 result with planktonic cells (Table 1) . High levels of pyrazinamide, isoniazid and ethambutol (20, 115 6000 and 1000 times the MIC's for planktonic cells, respectively) failed to sufficiently reduce light to 116 be classed as inhibitory (Table 1 , Fig. 2A-D, Fig. 3A-D) . More success was observed with non-first line 117 antibiotics, with MICs obtained for pellicle-grown BSG001 for streptomycin (125 mg/L), amikacin 118 (250 mg/L) and rifabutin (8 mg/L) (Table 1, Fig. 2E-G, Fig. 3E-G) . These pellicle-MICs represent an 119 increase of 250, 62.5 and 200 times the MIC's obtained for planktonic cultures, respectively (Table  120 1). 121
When novel and experimental compounds were examined, none of the current derivations of the 122 nitroimidazole based compounds 21, 22 (delamanid, pretomanid and SN30488) were able to reduce 123 light from the pellicle-grown M. tuberculosis at the concentrations tested (Table 1 , Fig.2H-J, Fig.3H -124 J). The same resistance to drug-killing was seen with experimental compounds based on 2-125 (quinoline-4-yloxy) acetamides 23 (QOA 1, QOA 2 and QOA 3) (Table 1 , Fig. 2K-M, Fig.3K-M) . In 126 contrast, the fluoroanthranilic-acid based compounds, 5-fluoroanthranilic acid (5-FAA) and 6-127 fluoroanthranilic acid (6-FAA), which target the tryptophan biosynthetic pathway 24 were seen to be 128 quite effective at inhibiting light from M. tuberculosis BCG001 growing as a pellicles (Table 1, Many infectious bacteria form biofilms within their host. Bacteria living within a biofilm are 134 notoriously difficult to treat and can persist for extended periods of time, as they have the ability to 135 resist the immune system, 25 display increased virulence 26, 27 and can become phenotypically more 136 resistant to antibiotics. It is common for antibiotic concentrations required to control bacteria within 137 biofilms to be 100 to 1000 fold greater than those needed to treat planktonic forms. 12 This was seen 138 to be true of the majority of compounds tested in this study. In many cases this is not too surprising. 139
Biofilms can affect drug activity by acting as a physical barrier to entry into the cell. The phenotypic 140 state of the cells within the biofilm could also make the cells less susceptible. Isoniazid's mode of 141 action relates to mycolic acid synthesis. When growing as a pellicle, it is possible that mycolic acid 142 synthesis is minimal or nonessential. Similarly ethambutol, delamanid and pretomanid are also 143 thought to affect various steps in cell wall biosynthesis and formation; none of these were seen to 144 have an effect. Pyrazinamide relies on conversion to pyrazinoic acid, which requires acidic conditions 145 to become active. This could indicate that these conditions are not present in mycobacterial pellicles 146 or that the drug is unable to penetrate the cells in this phenotype. If it is due to the lack of an acidic 147 environment this could represent a limitation in using this model for drug testing. In contrast, 148 antibiotics that affect protein synthesis, such as rifampicin, rifabutin, amikacin and streptomycin, 149 displayed some degree of inhibitive activity towards pellicle-grown M. tuberculosis, although this 150 activity was lower than the activity against planktonically-grown cells. The 2-(quinoline-4-yloxy) 151 acetamide based compounds also showed little activity against this biofilm form. The mode of action 152 of these compounds is likely due to electron transport inhibition of cytochrome bc1 oxidase. 23 As 153 the cells are actively metabolising, the lack of an effect from these compounds is most likely due to 154 an inability to access the cells. 155
In our study, we observed that M. tuberculosis growing as a pellicle is susceptible to a concentration 156 of ascorbic acid similar to that reported for planktonically-grown cells. This concentration was also 157 sufficient to cause death of the M. tuberculosis pellicle within 1 week of treatment. The activity of 158 ascorbic acid is thought to be due to the generation of highly reactive hydroxyl radicals via presence 159 of iron and Fenton reaction chemistry. 28 Killing due to this mechanism would be non-specific and not 160 dependant on uptake. Interestingly the fluoroanthranilic acid tryptophan biosynthesis inhibitors 161 were also seen to be effective at inhibiting and killing pellicles, indicating that this is a pathway 162 worthy of further consideration for drug targeting. 163
It is possible that the comparative ease in which test compounds can access bacteria within a 164 pellicle, that is from both above and below, as compared to a biofilm attached to a surface which 165 cannot be accessed from the surface side, make this form of biofilm easier to kill. While it is still 166 unknown if M. tuberculosis forms biofilms/pellicles in vivo, many mycobacterial species do form 167 complex, secondary structures such as pellicles in vitro. 29 Researchers have also reported histological 168 evidence for the presence of multicellular structures involving M. tuberculosis outside of the 169 macrophage. 14 Others have reported the presence of cells that resembles biofilms/pellicles in the 170 cavities formed during secondary tuberculosis which would indicate that this phenotype is likely to 171 play a role in human disease. 14, 15, 17 The biphasic response of M. tuberculosis infections, in which a 172 large kill is seen early on in drug treatment followed by a marked reduction in the bactericidal 173 activity of therapeutic agents due to phenotypic rather than genetic resistance, could also be 174 evidence that M. tuberculosis is able to form biofilms/pellicles in vivo. Such structures could act as a 175 reservoir for drug tolerant bacilli which are responsible for the increased duration of drug treatment 176 required in cases of TB. Regardless, the M. tuberculosis-pellicle model is a useful multi-phenotypic 177 environment in which a novel compound can be tested against cells with a range of susceptibilities. 178
The susceptibility of M. tuberculosis within this model indicates that drugs which can attack the 179 surface of the cell or can pass through the extracellular matrix of the pellicle represent the best 180 option for treatment. We also saw that the inhibition of tryptophan biosynthesis could be utilised in 181 TB treatment and their design should be further investigated. 
Planktonic
